Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

The -7 chromosomal abnormalities with signs of myelodysplasia in chronic myeloid leukemia as a major red signal.

Cayssials E, Guilhot F.

Haematologica. 2019 Jun;104(6):1096-1098. doi: 10.3324/haematol.2019.217034. No abstract available.

2.

Ponatinib and platelets a conflict in CML.

Guilhot F.

Blood. 2019 Apr 4;133(14):1520-1521. doi: 10.1182/blood-2019-02-900472. No abstract available.

PMID:
30948369
3.

Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.

Cayssials E, Jacomet F, Piccirilli N, Lefèvre L, Roy L, Guilhot F, Chomel JC, Leleu X, Gombert JM, Herbelin A, Barbarin A.

Br J Haematol. 2019 Jul;186(1):54-59. doi: 10.1111/bjh.15858. Epub 2019 Mar 12.

PMID:
30864168
4.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol. 2018 Sep;182(6):807-815. doi: 10.1111/bjh.15454. Epub 2018 Jul 9.

PMID:
29984825
5.

NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid.

de Graaf KL, Lapeyre G, Guilhot F, Ferlin W, Curbishley SM, Carbone M, Richardson P, Moreea S, McCune CA, Ryder SD, Chapman RW, Floreani A, Jones DE, de Min C, Adams DH, Invernizzi P.

Hepatol Commun. 2018 Mar 23;2(5):492-503. doi: 10.1002/hep4.1170. eCollection 2018 May.

6.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

7.

Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells.

Girerd S, Tosca L, Herault O, Vignon C, Biard D, Aggoune D, Dkhissi F, Bonnet ML, Sorel N, Desterke C, Bennaceur-Griscelli A, Tachdjian G, Guilhot F, Guilhot J, Chomel JC, Turhan AG.

Biochem Biophys Res Commun. 2018 Apr 15;498(4):715-722. doi: 10.1016/j.bbrc.2018.03.023. Epub 2018 Mar 17.

PMID:
29550484
8.

Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid.

Péraudeau E, Cronier L, Monvoisin A, Poinot P, Mergault C, Guilhot F, Tranoy-Opalinski I, Renoux B, Papot S, Clarhaut J.

J Control Release. 2018 Jan 10;269:36-44. doi: 10.1016/j.jconrel.2017.11.011. Epub 2017 Nov 10.

PMID:
29129656
9.

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Breccia M, Baccarani M, Rosti G, Cottone F, Cannella L, Guilhot F, Vignetti M, Efficace F.

Health Qual Life Outcomes. 2017 Oct 18;15(1):204. doi: 10.1186/s12955-017-0788-4.

10.

Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.

Cayssials E, Tartarin F, Guilhot J, Sorel N, Chomel JC, Leleu X, Guilhot F.

Leuk Lymphoma. 2018 Mar;59(3):766-769. doi: 10.1080/10428194.2017.1357178. Epub 2017 Aug 9. No abstract available.

PMID:
28792265
11.

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO, Nicolas-Virelizier E, McQuaker G, Rossi G, Johnson R, Huynh A, Ceballos P, Rambaldi A, Bachy E, Malladi R, Orchard K, Pohlreich D, Tilly H, Bonifazi F, Poiré X, Guilhot F, Haenel A, Crawley C, Metzner B, Gribben J, Russell NH, Damaj G, Thomson K, Dreger P, Montoto S.

Bone Marrow Transplant. 2017 Aug;52(8):1120-1125. doi: 10.1038/bmt.2017.88. Epub 2017 May 22.

PMID:
28530668
12.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.

Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.

13.

Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches.

Cayssials E, Guilhot F.

BioDrugs. 2017 Jun;31(3):143-149. doi: 10.1007/s40259-017-0225-6. Review.

PMID:
28501913
14.

Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.

Millot F, Dupraz C, Guilhot J, Suttorp M, Brizard F, Leblanc T, Güneş AM, Sedlacek P, De Bont E, Li CK, Kalwak K, Lausen B, Culic S, Dworzak M, Kaiserova E, De Moerloose B, Roula F, Biondi A, Baruchel A, Guilhot F.

Cancer. 2017 Sep 15;123(18):3609-3616. doi: 10.1002/cncr.30767. Epub 2017 May 12.

15.

Age-related health care disparities in multiple myeloma.

Puyade M, Defossez G, Guilhot F, Leleu X, Ingrand P.

Hematol Oncol. 2018 Feb;36(1):224-231. doi: 10.1002/hon.2422. Epub 2017 Apr 21.

PMID:
28429426
16.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

17.

The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia.

Jacomet F, Cayssials E, Barbarin A, Desmier D, Basbous S, Lefèvre L, Levescot A, Robin A, Piccirilli N, Giraud C, Guilhot F, Roy L, Herbelin A, Gombert JM.

Front Immunol. 2017 Jan 16;7:688. doi: 10.3389/fimmu.2016.00688. eCollection 2016.

18.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.

J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.

PMID:
28095277
19.

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group.

Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27.

20.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.

Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.

21.

Beyond tyrosine kinase inhibitors: Combinations and other agents.

Cayssials E, Guilhot F.

Best Pract Res Clin Haematol. 2016 Sep;29(3):271-283. doi: 10.1016/j.beha.2016.10.017. Epub 2016 Oct 20. Review.

PMID:
27839568
22.

The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.

Basbous S, Levescot A, Piccirilli N, Brizard F, Guilhot F, Roy L, Bourmeyster N, Gombert JM, Herbelin A.

J Pathol. 2016 Nov;240(3):262-268. doi: 10.1002/path.4779. Epub 2016 Sep 29.

PMID:
27513300
23.

Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis.

Buatois V, Chatel L, Cons L, Lory S, Richard F, Guilhot F, Johnson Z, Bracaglia C, De Benedetti F, de Min C, Kosco-Vilbois MH, Ferlin WG.

Transl Res. 2017 Feb;180:37-52.e2. doi: 10.1016/j.trsl.2016.07.023. Epub 2016 Aug 4.

PMID:
27559680
24.

Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, Caiello I, Davì S, Schulert G, Ravelli A, Grom AA, de Min C, De Benedetti F.

Ann Rheum Dis. 2017 Jan;76(1):166-172. doi: 10.1136/annrheumdis-2015-209020. Epub 2016 Jun 13.

PMID:
27296321
25.

Cytogenetics in CML: more important than you think.

Guilhot F.

Blood. 2016 Jun 2;127(22):2661-2. doi: 10.1182/blood-2016-04-708206. No abstract available.

26.

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot F.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):341-349.e1. doi: 10.1016/j.clml.2016.03.004. Epub 2016 Mar 29.

PMID:
27133948
27.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators.

Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.

PMID:
27083332
28.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM.

J Natl Cancer Inst. 2016 Mar 4;108(7). doi: 10.1093/jnci/djw003. Print 2016 Jul.

29.

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S.

Blood. 2016 Feb 11;127(6):703-12. doi: 10.1182/blood-2015-08-660977. Epub 2015 Nov 24.

30.

Multiple myeloma: the quality of care is linked to geographical and organisational determinants. A study in a French registry.

Puyade M, Defossez G, Guilhot F, Ingrand P.

Eur J Cancer Care (Engl). 2016 Sep;25(5):855-63. doi: 10.1111/ecc.12414. Epub 2015 Nov 25.

PMID:
26603508
31.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

32.

Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia.

Bruzzoni-Giovanelli H, González JR, Sigaux F, Villoutreix BO, Cayuela JM, Guilhot J, Preudhomme C, Guilhot F, Poyet JL, Rousselot P.

Oncotarget. 2015 Nov 3;6(34):36269-77. doi: 10.18632/oncotarget.5915.

33.

Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex.

Lacroix M, Rousseau F, Guilhot F, Malinge P, Magistrelli G, Herren S, Jones SA, Jones GW, Scheller J, Lissilaa R, Kosco-Vilbois M, Johnson Z, Buatois V, Ferlin W.

J Biol Chem. 2015 Nov 6;290(45):26943-53. doi: 10.1074/jbc.M115.682138. Epub 2015 Sep 11.

34.

The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.

Dkhissi F, Aggoune D, Pontis J, Sorel N, Piccirilli N, LeCorf A, Guilhot F, Chomel JC, Ait-Si-Ali S, Turhan AG.

Exp Hematol. 2015 Sep;43(9):775-80. doi: 10.1016/j.exphem.2015.04.013. Epub 2015 Jun 26.

PMID:
26118501
35.

Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D, Michallet M, Chevalier P, Raus N, El-Cheikh J, Tabrizi R, Huyn A, Buzyn A, Socié G, Vincent L, Guilhot F, Yakoub-Agha I, Lenain P, François S, Beckerich F, Lioure B, Bulabois CE, Deconinck E; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Biol Blood Marrow Transplant. 2015 Aug;21(8):1452-9. doi: 10.1016/j.bbmt.2015.04.020. Epub 2015 Apr 22.

36.

Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples.

Jacomet F, Cayssials E, Basbous S, Levescot A, Piccirilli N, Desmier D, Robin A, Barra A, Giraud C, Guilhot F, Roy L, Herbelin A, Gombert JM.

Eur J Immunol. 2015 Jul;45(7):1926-33. doi: 10.1002/eji.201545539. Epub 2015 May 20.

37.

Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.

Guilhot J, Preudhomme C, Mahon FX, Guilhot F.

Cancer. 2015 Feb 15;121(4):490-7. doi: 10.1002/cncr.29053. Epub 2014 Oct 24. Review.

38.

Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion.

Maurizot A, Beressi JP, Manéglier B, de la Marre NH, Spentchian M, Soury P, Solvet-Sebire P, Collet-Gaudillat C, Baud JM, Livarek B, Guilhot F, Rousselot P.

Blood Cancer J. 2014 Sep 19;4:e247. doi: 10.1038/bcj.2014.66. No abstract available.

39.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Brümmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillié L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C.

Br J Haematol. 2015 Jan;168(1):69-81. doi: 10.1111/bjh.13108. Epub 2014 Sep 8.

40.

Reply to J. Richter et al.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Sep 1;32(25):2823-5. doi: 10.1200/JCO.2014.56.3858. Epub 2014 Jul 28. No abstract available.

PMID:
25071119
41.

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.

Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J.

Haematologica. 2014 Jul;99(7):1236-8. doi: 10.3324/haematol.2013.098608. Epub 2014 Apr 11.

42.

BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients.

Levescot A, Flamant S, Basbous S, Jacomet F, Féraud O, Anne Bourgeois E, Bonnet ML, Giraud C, Roy L, Barra A, Chomel JC, Turhan A, Guilhot F, Girard JP, Gombert JM, Herbelin A.

Cancer Res. 2014 May 15;74(10):2669-76. doi: 10.1158/0008-5472.CAN-13-2797. Epub 2014 Mar 27.

43.

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.

Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F.

Int J Hematol. 2014;99(5):616-24.

PMID:
24658916
44.

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.

Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, Messas E.

Haematologica. 2014 Jul;99(7):1197-203. doi: 10.3324/haematol.2014.104075. Epub 2014 Mar 21.

45.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.

Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G.

Blood. 2014 Apr 10;123(15):2317-24. doi: 10.1182/blood-2013-10-532341. Epub 2014 Feb 25.

46.

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.

Legros L, Guilhot J, Huault S, Mahon FX, Preudhomme C, Guilhot F, Hueber AO; French CML Group (FI-LMC).

Leuk Res. 2014 Jun;38(6):662-5. doi: 10.1016/j.leukres.2014.01.010. Epub 2014 Feb 1.

PMID:
24553365
47.

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.

Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G.

Haematologica. 2014 Jul;99(7):1204-11. doi: 10.3324/haematol.2013.091272. Epub 2014 Feb 14.

48.

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A.

Blood. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11.

49.

Imatinib treatment and Aβ42 in humans.

Olsson B, Legros L, Guilhot F, Strömberg K, Smith J, Livesey FJ, Wilson DH, Zetterberg H, Blennow K.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S374-80. doi: 10.1016/j.jalz.2013.08.283. Epub 2013 Dec 10.

PMID:
24331439
50.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.

PMID:
24323036

Supplemental Content

Loading ...
Support Center